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Introduction
Death of macrophages and smooth muscle cells (SMC) occurs in human advanced atherosclerotic lesions (plaques), by apoptosis and necrosis [1^3] . Macrophage foam cells that die and are not phagocytosed can spill lipid into the extracellular environment and so contribute to the lipid core of the plaque [3, 4] , whilst death of SMC erodes the ¢brous cap [2] . Such changes destabilise plaques, increasing the risk of rupture and consequent thrombosis [5^7] .
Evidence implicating oxidation of low-density lipoprotein (LDL) in atherosclerosis progression includes that oxidised LDL (oxLDL) and lipid peroxidation products occur in atherosclerotic lesions [8^10] , and that oxLDL is toxic and apoptosis-inducing for macrophages and SMC in vitro [11^15] .
OxLDL contains a complex, variable, incompletely characterised mixture of toxic oxidation products. Lipid hydroperoxides appear relatively early on in the oxidation and aldehydes arise from their subsequent breakdown [16] . Aldehydes modify the LDL protein (apoB-100), increasing its negative charge [16] . Cholesterol oxidation products (also termed oxysterols) appear consequentially to the peroxidation of polyunsaturated fatty acids (PUFA) within LDL [17, 18] . The LDLborne enzyme lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), also termed platelet-activating factor acetylhydrolase, hydrolyses oxidised phosphatidylcholine (oxPC), but not nonoxidised phosphatidylcholine (PC), producing lysophosphatidylcholine (lyso-PC) and oxidised, non-esteri¢ed fatty acids (oxNEFA) [19, 20] .
Lipid oxidation products can activate cell transcription factors known as peroxisome proliferator-activated receptors (PPAR), especially PPARQ, which may induce apoptosis. Various synthetic PPARQ activators induced apoptosis in vitro, in macrophages [21] and in cancer cell lines [22, 23] . A natural PPARQ activator, 15-deoxy-v12,14-prostaglandin J 2 (15d-PGJ 2 ), a cyclo-oxygenase metabolite of arachidonic acid, induced apoptosis in vitro, in macrophages and endothelial cells [21, 24] . OxLDL and certain LDL oxidation products, 9-and 13-hydroxyoctadecadienoic acids, activated PPARQ in CV-1 cells [25] . In human atherosclerotic lesions, PPARQ occurs in macrophages in a pattern highly correlated with oxidationspeci¢c epitopes [26^28] .
A moderately oxidised form of LDL decreased SMC viability and induced SMC apoptosis in vitro, whereas a more strongly oxidised form of LDL did not, and neither did a very mildly oxidised form of LDL or native LDL (natLDL) [15] . In macrophages, moderately oxidised LDL induced death, including apoptosis, which was diminished by inhibiting Lp-PLA 2 within natLDL prior to oxidation [20] . The present study's purpose was to investigate the e¡ect of degree of LDL oxidation, focusing on mild and moderate degrees, on macrophage death (overall death, as well as apoptosis), and to explore the roles of Lp-PLA 2 and PPARQ therein. SMC were compared in selected cases.
Materials and methods
Ciglitazone and M199 medium were from Sigma. SB222657 and GW9662 were gifts of Glaxo SmithKline. Other materials were as described previously [20] . Dimethyl sulphoxide (¢nal concentration 9 0.5% v/v) was the solvent vehicle for ciglitazone, SB222657 and GW9662.
Isolation (from bu¡y coat) and culture conditions for human monocyte-macrophages (HMM) were as described previously [20] . HMM were cultured for 1 day before starting experiments, unless stated otherwise. Mature HMM were produced by culturing monocytes for 4^5 days before starting experiments. All HMM cultures and experiments were in Gibco Macrophage-SFM (serum-free medium), in 24-well plates. SMC derived from human aortic explants were cultured in M199 medium (Sigma) plus 20% foetal calf serum (FCS) in T75 (75-cm 2 ) tissue culture £asks (Falcon, Becton Dickinson). Medium was renewed every 2^3 days. Cultures were passaged when nearing con£uence, and were not used above passage 11. For toxicity experiments, SMC were plated into 24-well plates in M199 (without phenol red) plus 2% FCS and were used at c. 80% con£uence.
Isolation of natLDL and oxidation at 1 mg LDL protein/ml by Cu 2þ ions (10 WM) in phosphate-bu¡ered saline (PBS; pH 7.4) for 15 h at 37 ‡C, producing moderately-oxLDL (ox(3)LDL) were as described previously [20] . We adapted Fe 2þ -mediated LDL oxidation conditions from the literature [16, 29, 30] , as follows. Fe 2þ ions (iron-(II) sulphate, 10 WM) were used to oxidise LDL (1 mg LDL protein/ ml) for 15 h at 37 ‡C, either in saline (sodium chloride 0.9% w/v in high-purity Milli-Q deionised water) producing mildly-oxLDL (ox(2)LDL) or at pH 5.5 in PBS producing very mildly-oxLDL (ox(1)LDL). Treatment of natLDL with SB222657 (2 WM) or Pefabloc (PFB; 500 WM) prior to oxidation was as described previously [20] .
After 15 h oxidation, oxLDLs were Chelex-treated and diluted to 250 Wg LDL protein/ml with culture medium for incubation with cells. Triplicate or duplicate culture wells of cells were used for each oxLDL (or control) treatment for the nucleosome enzyme-linked immunosorbent assay (ELISA) and triplicate culture wells for the lactate dehydrogenase (LDH) release assay (see below). Incubations of oxLDLs with cells were for 48 h unless stated otherwise. Negative controls were cells incubated in these media with no additions (NA), or with natLDL. Gliotoxin (3 WM), an established apoptosis-inducing agent for HMM, was used for a positive control.
Total hydroperoxides were measured by the ferrous oxidation of xylenol orange (FOX) assay, version 'FOX2' [31] , and in selected cases additionally by an iodometric method [32] . Other assays were as described previously [20] .
Data are reported as mean þ S.E.M.; n is the number of individual specimens or culture wells. Statistical analysis was by ANOVA and Student's t-test (unpaired), using StatView 5.0.1 software. The level of signi¢cance was P 6 0.05. Experiments were repeated several times and representative data are presented.
Results and discussion
Ox(3)LDL, ox(2)LDL and ox(1)LDL were compared for cell death-inducing e¡ects and for chemical composition.
Ox(2)LDL induced signi¢cantly more overall death of HMM than ox(3)LDL, measured by the LDH release assay (Fig. 1) . Likewise, for SMC, LDH release after 48 h was signi¢cantly higher (P = 0.0009) for ox(2)LDL (73.2 þ 0.6%, n = 3) than for ox(3)LDL (44.2 þ 3.2%, n = 3). SMC LDH release was 12.2 þ 1.2% (n = 3) for NA and 13.4 þ 1.7% (n = 3) for natLDL. Ox(2)LDL induced signi¢cantly more HMM apoptosis (measured by nucleosome ELISA) than did ox(3)LDL (Fig. 2) . Ox(1)LDL was non-toxic to HMM, measured by LDH release (Fig. 1) , although it induced a low (yet statistically above-background) degree of HMM apoptosis (Fig. 2) , less than ox(3)LDL.
Time-course measurements (0^24 h; Fig. 3 ) by the FOX assay and relative electrophoretic mobility (REM) on agarose gels demonstrated that 15 h oxidation appeared optimal for di¡erentiating composition between the three types of oxLDL, and so was adopted to prepare oxLDLs for cell death induction studies, reported above. During moderate LDL oxida- Fig. 1 . Cytotoxicity of oxLDLs, measured by the LDH release assay in HMM, after 48 h exposure. Control cells were cultured without LDL or oxLDLs, i.e. NA. The su⁄xes -sb or -pfb indicate that the oxLDL was prepared with pretreatment (prior to oxidation) of natLDL with SB222657 or with PFB. Each histogram bar represents mean þ S.E.M., n = 9^15. ANOVA P 6 0.0001. **P 6 0.01, *P = 0.037, signi¢cantly di¡erent from the corresponding oxLDL prepared without SB222657 or PFB pretreatment.
# P = 0.0323, ox(2)LDL signi¢cantly di¡erent from ox(3)LDL. OxLDLs were signi¢cantly di¡erent from NA (P 6 0.05), except for ox(1)LDL and ox(1)LDL-sb. Fig. 2 . Apoptosis, measured by nucleosome ELISA, in HMM exposed to oxLDLs for 48 h. Each histogram bar represents mean þ S.E.M., n = 5^9. ANOVA P 6 0.0001. **P = 0.0002, *P = 0.027, signi¢cantly di¡erent from the corresponding oxLDL prepared without SB222657 pretreatment.
# P = 0.0232, ox(2)LDL signi¢cantly di¡erent from ox(3)LDL. Gliotoxin (3 WM for 4 h), a positive control, gave absorbance 0.389 þ 0.019 (n = 6). OxLDLs were signi¢cantly di¡erent from NA (P 6 0.05), except for ox(2)LDL-sb, ox(1)LDL-sb and ox(1)LDL-pfb.
tion, hydroperoxides peak early on, and then decline rapidly. For mild LDL oxidation, hydroperoxides peak later and remain high, as decline is slow. After 15 h oxidation, ox(2)LDL consistently contained higher levels of hydroperoxides (FOX assay), lower levels of oxysterols measured by gas chromatography (GC), lower levels of malondialdehyde (MDA) equivalents measured by the thiobarbituric acid-reactive substances (TBARS) assay and lower REM (i.e. less negative charge), than did ox(3)LDL (Fig. 4) . Hydroperoxide levels in ox(1)LDL were only slightly above natLDL, whilst REM, TBARS and 7L-hydroxycholesterol in ox(1)LDL were similar to natLDL (Fig. 4) . Hydroperoxide results by the iodometric method (data not shown) were similar to the FOX assay.
The nucleosome ELISA measures cytoplasmic histone-associated DNA fragments (mono-and oligo-nucleosomes), apoptosis markers arising from internucleosomal cleavage as a result of activation of endogenous endonucleases and proteases. We also used acridine orange (AO) staining of HMM (¢xed in ethanol^PBS 70:30 v/v) to measure apoptosis by £uorescence microscopy as percentage of HMM with morphologically condensed nuclear chromatin, another characteristic of apoptosis [33] . In principle, nuclear condensation can occur before DNA fragmentation. Such cell counts are, however, less quantitatively discriminating than the nucleosome ELISA. Assessed by AO staining, ox(2)LDL and ox(3)LDL appeared both very potent, respectively giving apoptotic cells as 88% and 87% of total cells, whilst natLDL and NA gave 7% and 4% respectively, all after 48 h incubation, and gliotoxin (3 WM; positive control) gave 88% apoptosis after 24 h. Ox(1)LDL was not assessed using AO.
Our results suggest that hydroperoxides, which are earlystage oxidation products, are more potent toxins in oxLDL than are the more advanced oxidation products such as aldehydes and oxysterols. Plotting hydroperoxide levels (FOX assay) in natLDL, ox(1)LDL, ox(2)LDL and ox(3)LDL v. % LDH release measured in HMM (1 day in culture before starting experiments), after 48 h exposure to these oxLDLs or natLDL, revealed a highly signi¢cant positive correlation (least-squares linear regression R 2 = 0.586, P 6 0.0001, n = 51). Weaker (though still signi¢cant) positive correlations with % LDH release were seen for 7L-hydroxycholesterol, MDA equivalents and REM. Hydroperoxide-rich ox(2)LDL might constitute a 'loaded weapon' that can decompose at the cell surface membrane and/or within the cell to give high local concentrations of aldehydes and free radicals. The results for ox(1)LDL suggest that a low, though above-background, level of hydroperoxides (and possibly other uncharacterised entities produced in the earliest stages of LDL oxidation) could trigger a low degree of apoptosis but not yet lead to loss of integrity of the cell surface membrane within the 48 h duration of the experiment. In contrast, for ox(2)LDL and ox(3)LDL, apoptosis and loss of cell surface membrane integrity (LDH release) go hand-in-hand by 48 h.
The hydroperoxides detected are probably derived from PUFAs (esteri¢ed and non-esteri¢ed) rather than from cholesterol (esteri¢ed and non-esteri¢ed), as our oxysterol assay protocol, which included a sodium borohydride (NaBH 4 ) reduction step in the sample processing, would encompass cholesterol hydroperoxides by converting them to the corresponding hydroxides. Hydroperoxides are thermally unstable, so would decompose on GC. NaBH 4 also converts any 7-ketocholesterol present to 7L-hydroxycholesterol (c. 85%) and to 7K-hydroxycholesterol (c. 15%) [34] . Because it elutes very close to cholesterol, we do not normally quantify 7K-hydroxycholesterol by this analytical protocol [35] . The 7L-hydroxycholesterol levels in Fig. 4 are thus e¡ectively a summation of the oxysterols 7-ketocholesterol, 7L-hydroperoxycholesterol and 7L-hydroxycholesterol present in the original samples. All the above oxysterols are cytotoxic [36^38] . Part of the TBARS detected might arise from decomposition of fatty acid hydroperoxides originally present in the samples, forming MDA during the necessary heating step of the assay [39] , thereby possibly underestimating the di¡erential between ox(2)LDL and ox(3)LDL for MDA levels. Hydroperoxides are 'reaction intermediates' chemically, rising then declining as the oxidation progresses [16] , whereas 7L-hydroxycholesterol and REM are cumulative markers of oxidation that rise and do not decline even for strong, prolonged oxidation [18] .
Toxicity was not due to residual free Fe 2þ or Cu 2þ ions remaining in solution after the Chelex treatment of the oxLDLs, because controls consisting of solutions of Fe 2þ or Cu 2þ that we put through the whole of the preparation procedure, but omitting the LDL, were non-toxic to HMM. However, oxLDL-associated iron or copper ions, if not removed by Chelex, might play a role in toxicity, possibly in conjunction with lipid hydroperoxides in oxLDL. Human advanced atherosclerotic lesions contain 'catalytic' iron and copper ions [40] .
Lp-PLA 2 is a phospholipase that hydrolyses oxPC possessing an oxidised PUFA chain ester-linked in the sn-2 position, but does not hydrolyse non-oxidised PC. Lp-PLA 2 is a serine esterase, and is LDL-borne. Also, mature macrophages and to a lesser degree freshly isolated monocytes secrete Lp-PLA 2 identical to LDL-borne Lp-PLA 2 [41^43]. Pre-treatment of natLDL with SB222657, a speci¢c Lp-PLA 2 inhibitor [19] , diminished the toxicity and apoptosis induction that ensued when the LDL was mildly or moderately oxidised and then added to HMM (Figs. 1, 2 and 5 ). PFB, a broad-spectrum serine esterase/protease inhibitor, had a similar e¡ect to SB222657 on toxicity but did not inhibit the corresponding apoptosis induction (Figs. 1 and 2) . PFB might inhibit antiapoptotic serine esterases/proteases, presumably within the cell. SB222657 and PFB did not act as antioxidants, either here (Fig. 4) or in earlier studies [19, 20] , and have no known chelating ability, consistent with their lack of e¡ect on LDL oxidation per se (as opposed to hydrolysis).
Our results agree with evidence that Lp-PLA 2 can hydrolyse oxPC, whether possessing full-length PUFA-hydroperoxide chains or oxidatively fragmented PUFA chains, liberating lyso-PC and oxNEFA [19] . Lyso-PC was more toxic than an oxPC possessing an oxidatively fragmented PUFA chain, for HMM [20] . PC is the main phospholipid class in LDL. However, Lp-PLA 2 has rather permissive substrate requirements [44, 45] , so it might also hydrolyse oxidised forms of the less abundant LDL phospholipid classes, and maybe also hydrolyse oxidised tri-and di-acylglycerols.
The role of PPAR in oxLDL-induced cell death was explored using the PPARQ-preferential antagonist GW9662, which also inhibits PPARK and PPARN less potently, binding irreversibly to PPAR [46] . Cells were pretreated for 20 h with 2 WM GW9662, which was replenished at 2 WM when the oxLDLs were added. GW9662 (2 WM) almost completely inhibits PPARQ activation [46, 47] . GW9662 (2 WM) was not toxic to HMM or SMC, and it did not signi¢cantly a¡ect the toxicity of ox(2)LDL or ox(3)oxLDL, for HMM (Fig. 5 ) or for SMC (data not shown; P s 0.05). GW9662 (2 WM) treatment of HMM tended to counteract the lowering of the oxLDL toxicity resulting from Lp-PLA 2 inhibition with SB222657, for HMM that had been cultured either for 4 days (Fig. 5) or for 1 day (data not shown) before starting experiments. Possibly, PPARQ activation by intact (i.e. non-hydrolysed) oxPC triggers a cellular defence mechanism. Oxidised alkyl PC (the O-alkyl linkage in the sn-1 position, and the oxidised chain ester-linked in the sn-2 position), a sub-class of oxPC in oxLDL, can speci¢cally bind to and activate PPARQ [48] . The binding appeared a characteristic of the intact (nonhydrolysed) form since oxNEFAs were ine⁄cient competitors [48] . OxPC can activate PPARK [49] , but this requires phospholipase A 2 activity [50] , suggesting that the oxNEFA thereby liberated were the actual PPARK ligands. PPARQ thus appears more likely to be important than PPARK in the putative defence mechanism triggered by intact oxPC in our study.
The PPARQ agonist ciglitazone at 3 WM, its EC 50 [51] , was innocuous to HMM. The addition of ciglitazone (3 WM) to mature HMM with ox(3)LDL and ox(2)LDL prepared with inhibition of Lp-PLA 2 , by pre-treatment of natLDL with SB222657, signi¢cantly diminished toxicity, by 27% (P = 0.0374) and 24% (P = 0.0032) respectively after 24 h, consistent with a protective role for PPARQ activation by oxPC. When the SB222657 pre-treatment was omitted, ciglitazone did not diminish toxicity of the oxLDLs. Ciglitazone and rosiglitazone had biphasic e¡ects on T-lymphocyte death [52] . Another PPARQ activator, 15d-PGJ 2 , was toxic to HMM [53] . The highly unsaturated arachidonic and docosahexaenoic acids, incubated with HMM under conditions allowing peroxidation, induced both apoptosis and PPARQ activation, whereas the less highly unsaturated linoleic and oleic acids, which were less readily peroxidisable, were innocuous and did not activate PPARQ [53] .
PPARQ activation might thus be a cellular death mechanism or a defence, depending on conditions. Caveats are that inhibitors and activators might have additional non-speci¢c effects, and that co-demonstration of PPARQ activation and apoptosis does not prove causation. The putative dual function of PPARQ^defence or death^would be broadly akin to other cellular damage responses, e.g. involving p53 and mismatch repair, where the cell is either repaired or deleted depending on the degree of damage. PPARQ appears to act defensively under the present study's conditions. Our induction of cell death by very mildly-, mildly-and moderately-oxLDLs indicates that the presence of strongly oxidised LDL is not necessary to kill cells, a ¢nding relevant to atherosclerotic lesions where the overall degree of oxidation appears less than that of strongly oxidised LDL. Very mildlyoxLDL induced HMM apoptosis above background, whilst mildly-and moderately-oxLDLs produced both apoptosis and overt toxicity. In human advanced atherosclerotic lesions, macrophage foam cells die by apoptosis and necrosis [3] . Classical apoptosis and necrosis represent the ends of a continuum of death modes, with varying contributions of the cellular machinery, and both apoptosis and necrosis can involve controlled cellular events [54, 55] .
Macrophage death in lesions may be anti-in£ammatory and anti-atherogenic if the dying or dead macrophages are e⁄-ciently scavenged by viable neighbouring macrophages. If not scavenged, dead macrophages contribute to the lesion's acellular lipid core, exacerbating the lesion. Inhibition of Lp-PLA 2 might be ameliorative, as the fewer ensuing dead cells would be more easily scavenged by the remaining viable macrophages. Since oxPC are epitopes, on oxLDL and on apoptotic cells, recognised by CD36 (scavenger receptor type B)
[56^58], preservation of oxPC by inhibiting their hydrolysis, by means of inhibiting Lp-PLA 2 , might improve the e⁄ciency of scavenging of oxLDL and of apoptotic macrophages. Whilst theoretically this might increase foam cell formation, this might be counterbalanced if the oxPC also activate PPARQ, since activation of PPARQ in macrophages upregulates both CD36 [59] and the ABCA1 cholesterol e¥ux pathway, and the latter counteracts the e¡ect of the former [60] .
In conclusion, we have shown that mildly-oxLDL, rich in lipid hydroperoxides, is a potent death inducer for macrophages and SMC. Moderately-oxLDL was a less potent, though clearly signi¢cant, inducer of death in these cell types. Induction of macrophage death appears partly as a consequence of the hydrolytic action of Lp-PLA 2 on oxPC. Elevated plasma levels of Lp-PLA 2 were a strong independent predictor of coronary artery disease in men [61] . Non-hydrolysed, oxidised phospholipids in oxLDL may activate PPARQ in macrophages, as a cellular defensive response. These results may be relevant to the progression of atherosclerotic lesions to an unstable, rupture-prone state with thinned ¢brous caps and enlarged lipid cores, and may suggest dietary and pharmacological strategies for combating the disease. Fig. 5 . E¡ect of treatment of cells with the PPARQ antagonist GW9662 (2 WM) on cytotoxicity of oxLDLs, measured by the LDH release assay, in mature HMM, after 50 h exposure. Abbreviations: gw, GW9662; sb, SB222657. The su⁄x -gw indicates that cells were pretreated with GW9662 for 20 h before adding the relevant oxLDL prepared with or without SB222657 pretreatment of natLDL. Each histogram bar represents mean þ S.E.M., n = 3. ANOVA P 6 0.0001. **Ox(3)LDL-sb signi¢cantly di¡erent from ox(3)LDL (P = 0.0013) or from ox(3)LDL-sb-gw (P = 0.0014); *ox(2)LDL-sb signi¢cantly di¡erent from ox(2)LDL (P = 0.0009) or from ox(2)LDL-sb-gw (P = 0.0223); # ox(2)LDL signi¢cantly di¡erent from ox(3)LDL (P = 0.005). OxLDLs were signi¢cantly di¡erent from NA (P 6 0.0001); gw and sb were not signi¢cantly di¡erent from NA.
